logo

For the Inventor, By the Inventor

Uppsala, Sweden

Carl-Henrik Heldin

This inventor holds 40 USPTO granted patents and 2 EPO patents, primarily in Cancer Therapeutics. Top assignees: Ludwig Institute for Cancer Research Limited, Chiron Corporation, Gilead Sciences, Inc.. Active years: 1993-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carl-Henrik Heldin. Retrieved from https://idiyas.com/inventor/carl-henrik-heldin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40

% Patents Active = 72.5

 

Average Co-Inventor Count = 5.0

ph-index = 11

Forward Citations = 340(Granted Patents)


Location History:

  • Upsala, SE (1993 - 1999)
  • Uppsala, SE (1993 - 2015)

Company Filing History:

goldMedal28 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal3 out of 672 
 
Chiron Corporation
 patents
bronzeMedal2 out of 946 
 
Gilead Sciences, Inc.
 patents
4. 2 out of 20 
 
Licentia, Ltd.
 patents
5. 1 out of 1 
 
Biocistronix Ab
 patent
6. 1 out of 72 
 
Creative Biomolecules, Inc.
 patents
7. 1 out of 141 
 
Curis, Inc.
 patents
8. 1 out of 5 
 
Melica Hb
 patents
9. 1 out of 3,977 
 
Novartis Ag
 patents
10. 2 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1993-2015

Loading Chart...
Loading Chart...
Areas of Expertise:
Cancer Treatment
PDGF
Activin Receptor
Nucleic Acid Ligands
Tumor Targeting
Protein Kinases
Endothelial Growth Factor
Smad Proteins
Signal Transduction
GTPase Activating Protein
Protein Tyrosine Phosphatases
Morphogen Receptors
40 patents (USPTO):Explore Patents
1. 9096901 - Methods and materials related to hair pigmentation and cancer (2015-08-04),
2. 8278043 - Methods and materials related to grey alleles (2012-10-02),
3. 8080639 - Antibodies which bind specifically to activin receptor like kinase 3 (2011-12-20),
4. 7932351 - Activin receptor-like kinase-1 proteins having serine-threonine kinase domains (2011-04-26),
5. 7723339 - Combination comprising a signal transduction inhibitor and an epothilone derivative (2010-05-25),
6. 7592428 - Antibodies which bind specifically to activin receptor like kinases (2009-09-22),
7. 7148037 - Platelet-derived growth factor D, DNA coding therefor, and uses thereof (2006-12-12),
8. 7141375 - Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor (2006-11-28),
9. 7067260 - Methods of identifying morphogen receptor-binding analogs (2006-06-27),
10. 6982319 - Antibodies which bind specifically to activin receptor-like kinases (2006-01-03),
11. 6974816 - Combination for the treatment of endothelial damage (2005-12-13),
12. 6939849 - Recombinant PDGF A-chain homodimers and methods of use (2005-09-06),
13. 6706687 - Platelet-derived growth factor D (2004-03-16),
14. 6699843 - Method for treatment of tumors using nucleic acid ligands to PDGF (2004-03-02),
15. 6673570 - Smad associating polypeptides (2004-01-06),

Title: The Innovative Journey of Carl-Henrik Heldin

Introduction: Carl-Henrik Heldin, a distinguished inventor hailing from Uppsala, Sweden, has made significant contributions to the field of science and technology through his groundbreaking inventions and innovative mindset.

Latest Patents: Carl-Henrik Heldin holds several patents in the field of biotechnology and medical research, focusing on novel treatments for various diseases and conditions. His recent patents include advancements in gene therapy and personalized medicine.

Career Highlights: With a background in biochemistry and molecular biology, Carl-Henrik Heldin has had a remarkable career trajectory. He has served as a leading researcher in prestigious institutions, pioneering new technologies and methodologies in the healthcare industry.

Collaborations: Throughout his career, Carl-Henrik Heldin has collaborated with top scientists, researchers, and industry experts to bring his inventions to life. His collaborative efforts have led to the development of cutting-edge solutions that have revolutionized the medical field.

Conclusion: In conclusion, Carl-Henrik Heldin stands as a visionary inventor whose relentless pursuit of innovation has left an indelible mark on the world of biotechnology and medical research. His passion for pushing the boundaries of science continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…